Top

Published in:

01-05-2014 | Research Article

Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case–control studies

Authors: Hong Wang, Li Ren, Yifeng He, Ye Wei, Zenggan Chen, Weige Yang, Yipeng Fu, Xiaoyue Xu, Weigao Fu, Guangfu Hu, Wenhui Lou

Published in: Tumor Biology | Issue 5/2014

Abstract

Previous epidemiological studies have evaluated the association between common variations of cytochrome P450 (CYP)2C9 (430C>T and 1075A>C) and the risk of colorectal cancer (CRC) with conflicting results. To derive a more precise estimation of the relationship between these CYP2C9 polymorphisms and CRC, a meta-analysis was performed. PubMed, Embase, CNKI, and Web of Science databases were searched. A total of 16 studies including 9,463 cases and 11,416 controls were identified. Potential sources of heterogeneity including ethnicity, sample size of study, genotyping method, diagnostic criteria, and outcome were systematically assessed. Overall, the summary odds ratio of 430T variant for CRC was 0.92 (95 % confidence interval (CI) 0.86–0.98; P = 0.012) and 1.39 (95 % CI 1.07–1.81; P = 0.013) for colorectal adenomas (CRAs). As for CYP2C9 1075A>C polymorphism, no significant results were observed in overall and subgroup analysis. There was no evidence of publication bias. In conclusion, there is evidence to indicate a significant association between CYP2C9 430C>T polymorphism and CRC/CRA risk.

Available only for authorised users

Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed

Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, Carey FA, et al. Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics. 2010;20(5):315–26.CrossRefPubMed

de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004;4(10):769–80.CrossRefPubMed

Reszka E, Wasowicz W, Gromadzinska J. Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr. 2006;96(4):609–19.PubMed

Hermann S, Rohrmann S, Linseisen J. Lifestyle factors, obesity and the risk of colorectal adenomas in EPIC-Heidelberg. Cancer Causes Control. 2009;20(8):1397–408.CrossRefPubMed

Giacosa A, Franceschi S, La Vecchia C, Favero A, Andreatta R. Energy intake, overweight, physical exercise and colorectal cancer risk. Eur J Cancer Prev. 1999;8 Suppl 1:S53–60.PubMed

Slattery ML. Diet, lifestyle, and colon cancer. Semin Gastrointest Dis. 2000;11(3):142–6.PubMed

Nagao M, Sugimura T. Carcinogenic factors in food with relevance to colon cancer development. Mutat Res. 1993;290(1):43–51.CrossRefPubMed

10.

Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000;293(2):453–9.PubMed

11.

Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996;333(2):447–58.CrossRefPubMed

12.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

13.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRefPubMedPubMedCentral

14.

Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4):251–3.CrossRefPubMed

15.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.CrossRefPubMedPubMedCentral

16.

Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schönfels W, et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. 2011;18(2):265–76.CrossRefPubMed

17.

Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol. 2010;172(9):1000–14.CrossRefPubMedPubMedCentral

18.

Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3098–107.CrossRefPubMedPubMedCentral

19.

Liao LH, Zhang H, Lai MP, Lau KW, Lai AK, Zhang JH, et al. The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin Chim Acta. 2007;380(1–2):191–6.CrossRefPubMed

20.

Samowitz WS, Wolff RK, Curtin K, Sweeney C, Ma KN, Andersen K, et al. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol. 2006;4(7):894–901.CrossRefPubMed

21.

Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, Hunter DJ. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses’ Health Study and the Physicians’ Health Study. Mol Carcinog. 2005;44(1):21–30.CrossRefPubMed

22.

Martínez C, García-Martín E, Ladero JM, Sastre J, Garcia-Gamito F, Diaz-Rubio M, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis. 2001;22(8):1323–6.CrossRefPubMed

23.

Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol. 2004;2(8):704–12.CrossRefPubMed

24.

Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics. 2005;15(8):535–46.CrossRefPubMed

25.

Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Sébille V, Colman H, et al. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1460–7.CrossRefPubMed

26.

Buyukdogan M, Boruban MC, Artac M, Demirel S. Frequency of cytochrome 450 (CYP2C9 and CYP2C19) genetic polimorphisms in patients with colorectal carsinoma. Int J Hematol Oncol. 2009;19:134–9.

27.

McGreavey LE, Turner F, Smith G, Boylan K, Timothy Bishop D, Forman D, et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics. 2005;15(10):713–21.CrossRefPubMed

28.

Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4(6):285–99.CrossRefPubMed

29.

Yokose T, Doy M, Taniguchi T, Shimada T, Kakiki M, Horie T, et al. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch. 1999;434(5):401–11.CrossRefPubMed

30.

Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol. 1991;4(4):391–407.CrossRefPubMed

31.

Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000;10(2):95–104.CrossRefPubMed

32.

Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem. 1992;267(1):83–90.PubMed

Title: Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case–control studies
Authors: Hong Wang
Li Ren
Yifeng He
Ye Wei
Zenggan Chen
Weige Yang
Yipeng Fu
Xiaoyue Xu
Weigao Fu
Guangfu Hu
Wenhui Lou
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1566-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells

Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma

Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: a meta-analysis

Association study of SNPs of genes IFNGR1 (rs137854905), GSTT1 (rs71748309), and GSTP1 (rs1695) in gastric cancer development in samples of patient in the northern and northeastern Brazil

Clinical significance and biological roles of CARMA3 in human bladder carcinoma

Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer